04:47 PM EST, 12/23/2025 (MT Newswires) -- Organogenesis ( ORGO ) said late Tuesday that it has initiated rolling submission of a Biologics License Application to the US Food and Drug Administration for ReNu, a non-surgical biologic therapy developed to address knee osteoarthritis pain.

The company said it plans to complete the submission with final modules expected in the first half of 2026.

Organogenesis ( ORGO ) shares were up 1.9% in after-hours trading.